GIP Analog Peptides Resolving DPP-IV Degradation

The patent applies parameter changes by modifying the amino acid sequence of GIP at positions susceptible to DPP-IV cleavage (N-terminal residues and internal bonds). Specific substitutions such as replacing Tyr1 with D-Tyr1, Ala2 with D-Ala2, and other residues with D-amino acids or non-natural amino acids alter the chemical parameters of the peptide to resist enzymatic degradation, thereby extending duration of action while maintaining biological activity.

The patent creates composite peptide structures by combining modified GIP sequences with other peptide hormones or functional domains to generate hybrid molecules. These composite structures integrate the glucose-lowering activity of GIP with additional therapeutic functions, while the modified backbone provides resistance to DPP-IV degradation, solving both stability and duration issues simultaneously.

The patent applies local quality by making site-specific modifications to the GIP molecule at particular amino acid positions (e.g., N-terminal residues, specific internal positions) while leaving other regions unchanged. This localized modification strategy allows the peptide to maintain its glucose-lowering activity and receptor binding capability while specifically altering susceptibility to DPP-IV cleavage, thereby improving the therapeutic profile without introducing gastrointestinal side effects.

The patent creates stable, long-acting GIP analogs that replace the need for frequent dosing of short-acting native GIP or GLP-1. By engineering DPP-IV resistance through amino acid modifications, the patent produces a single, stable therapeutic agent that provides sustained glucose control over an extended period, eliminating the need for multiple administrations and avoiding the gastrointestinal side effects associated with GLP-1.

The patent systematically applies parameter changes by substituting specific amino acid residues with D-amino acids, non-natural amino acids, or other modified residues at predetermined positions in the GIP sequence. These targeted substitutions alter the stereochemistry and chemical properties of key residues to prevent DPP-IV recognition and cleavage, extending half-life through controlled modifications rather than random complexity increases.

The patent segments the GIP molecule into functional domains, identifying and modifying only the critical regions susceptible to DPP-IV degradation (N-terminal region and specific internal bonds) while preserving the intact bioactive core. This segmented approach allows selective modification of stability-critical regions without altering the overall molecular architecture or requiring complex global restructuring, thereby extending half-life with minimal increase in overall molecular complexity.